Document Detail


Lowering the dose of sirolimus, released from a nonpolymeric hydroxyapatite coated coronary stent, reduces signs of delayed healing.
MedLine Citation:
PMID:  19463438     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: The aim of this study was to compare efficacy of low- and high-dose sirolimus release (25, 40, or 100 microg) from hydroxyapatite (HAp) with Cypher (Cordis, Johnson & Johnson, Warren, New Jersey) (111 microg sirolimus) in porcine coronary arteries.
BACKGROUND: Polymer-based sirolimus-eluting stents such as Cypher interfere with vascular healing, probably due to the permanent presence of the polymer coating and the high sirolimus dose. The use of low-dose sirolimus and inert nonpolymeric but biodegradable coatings such as HAp might be more appropriate.
METHODS: Stents (n = 68) were implanted, guided by quantitative coronary angiography. All swine received clopidogrel and acetylsalicylic acid during 28 days follow-up. Safety of the coating in absence of drugs was studied by comparing HAp with and without a lipid-based release regulating layer (HApR) with bare-metal stents. Efficacy was studied by comparing the release of 25, 40, and 100 microg sirolimus with Cypher.
RESULTS: The safety study (without drug) revealed no differences in neointimal thickening in response to HAp and HApR with complete healing in all groups. Dose response analysis showed that neointimal thickening was similar in all groups regardless of sirolimus dose, with a normal appearance of the endothelium. There was, however, a dose-dependent increase in fibrinoid (p = 0.028), considered to be a marker of delayed healing. The Cypher stent induced the highest amount of fibrinoid.
CONCLUSIONS: Reducing the dose of sirolimus eluting from a biocompatible HAp coated stent reduces signs of delayed vascular healing, without affecting neointimal hyperplasia.
Authors:
Wim J van der Giessen; Oana Sorop; Patrick W Serruys; Ilona Peters-Krabbendam; Heleen M M van Beusekom
Related Documents :
7944268 - Effects of poloxamer 188 in a rabbit model of hemorrhagic shock.
18723908 - Efficacy of two dose regimes of intravenous immunoglobulin in rh hemolytic disease of n...
24576168 - The impact of prehydration on the clearance and toxicity of high-dose methotrexate for ...
820228 - The efficacy of low-dose versus conventional therapy of insulin for treatment of diabet...
2730688 - Intracellular localization of the calcium- and calmodulin antagonist fendiline.
153478 - Effect of p-chlorophenylalanine on cerebral serotonin binding, serotonin concentration ...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  JACC. Cardiovascular interventions     Volume:  2     ISSN:  1876-7605     ISO Abbreviation:  JACC Cardiovasc Interv     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-05-25     Completed Date:  2009-08-03     Revised Date:  2012-08-29    
Medline Journal Info:
Nlm Unique ID:  101467004     Medline TA:  JACC Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  284-90     Citation Subset:  IM    
Affiliation:
Department of Cardiology, Erasmus Medical Center, Rotterdam, the Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angioplasty, Balloon, Coronary / adverse effects,  instrumentation*
Animals
Aspirin / administration & dosage
Cardiovascular Agents / administration & dosage*
Coated Materials, Biocompatible*
Coronary Angiography
Coronary Restenosis / etiology,  prevention & control
Coronary Vessels / drug effects*,  pathology
Drug-Eluting Stents*
Durapatite / chemistry*,  toxicity
Hyperplasia
Lipids / chemistry
Materials Testing
Models, Animal
Platelet Aggregation Inhibitors / administration & dosage
Prosthesis Design
Sirolimus / administration & dosage*
Stainless Steel
Surface Properties
Sus scrofa
Ticlopidine / administration & dosage,  analogs & derivatives
Wound Healing / drug effects*
Chemical
Reg. No./Substance:
0/Cardiovascular Agents; 0/Coated Materials, Biocompatible; 0/Lipids; 0/Platelet Aggregation Inhibitors; 12597-68-1/Stainless Steel; 1306-06-5/Durapatite; 50-78-2/Aspirin; 53123-88-9/Sirolimus; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: effic...
Next Document:  Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer.